Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity (Q40280431)

19 September 2017

0 references

Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity (English)

1 reference

19 September 2017

1 reference

6

J E Manson

1 reference

19 September 2017

5

E Paskett

1 reference

19 September 2017

R T Chlebowski

1

1 reference

19 September 2017

R Haque

2

1 reference

19 September 2017

H Hedlin

3

1 reference

19 September 2017

N Col

4

1 reference

19 September 2017

J T Kubo

7

1 reference

19 September 2017

K C Johnson

8

1 reference

19 September 2017

J Wactawski-Wende

9

1 reference

19 September 2017

K Pan

10

1 reference

19 September 2017

G Anderson

11

1 reference

19 September 2017

language of work or name

English

0 references

publication date

24 November 2015

1 reference

Breast Cancer Research and Treatment

19 September 2017

published in

1 reference

19 September 2017

volume

154

1 reference

19 September 2017

issue

3

1 reference

19 September 2017

page(s)

609-616

1 reference

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Meta-analysis of vascular and neoplastic events associated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Exemestane for breast-cancer prevention in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Design of the Women’s Health Initiative Clinical Trial and Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Management of cancer treatment-induced bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Implementation of the women's health initiative study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-015-3647-1

10.1007/S10549-015-3647-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

19 September 2017

1041451322

0 references

1 reference